Raft Of New Drugs To Learn EU Marketing Fate
Sixteen EU Marketing Applications Are Nearing The End Of The Review Process
ViiV Healthcare’s “last resort” HIV drug, fostemsavir, is one of 16 new medicines that are up for an opinion by the European Medicines Agency on whether they should be authorized for use across the EU.
